Andrew McAuley1, Lorna Aucott2, Catriona Matheson2. 1. NHS Health Scotland, Public Health Science Directorate, Meridian Court, Glasgow, Scotland G2 6QE, UK; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland G4 0BA, UK. Electronic address: andrew.mcauley@nhs.net. 2. Institute of Applied Health Sciences, University of Aberdeen, Aberdeen AB24 3FX, UK.
Abstract
BACKGROUND: The epidemic of drug-related mortality continues to endure. The most common cause of death associated with drugs is overdose and opioids are consistently the substances most prominently involved. As well as efforts to control the availability of illicit drugs and increase engagement in treatment services, the use of naloxone for peer administration has increasingly been championed as a mechanism for addressing the DRD epidemic. Despite increasing adoption and use of take-home naloxone (THN) as a primary response to DRD internationally the evidence base remains limited. METHODS: A systematic review and descriptive meta-analysis of the international THN literature was undertaken to determine an effect size for THN programmes. For each study, a proportion of use (PoU) was calculated using the number of 'peer administered uses' and the 'total number of participant/clients' trained and supplied with naloxone with a specific focus on people who use drugs (PWUD). This was constrained to a three month period as the lowest common denominator. As a percentage this gives the three month rate of use (per 100 participants). RESULTS: From twenty-five identified THN evaluations, nine studies allowed a PoU to be determined. Overall, the model shows a range of 5.2-13.1 (point estimate 9.2) naloxone uses every three months for every 100 PWUD trained. CONCLUSION: Our model estimates that around 9% of naloxone kits distributed are likely to be used for peer administration within the first three months of supply for every 100 PWUD trained. Future evaluations should directly compare different training structures to test relative effectiveness and use a series of fixed time periods (3, 6 and 12 months) to determine whether time since training affects rate of naloxone use.
BACKGROUND: The epidemic of drug-related mortality continues to endure. The most common cause of death associated with drugs is overdose and opioids are consistently the substances most prominently involved. As well as efforts to control the availability of illicit drugs and increase engagement in treatment services, the use of naloxone for peer administration has increasingly been championed as a mechanism for addressing the DRD epidemic. Despite increasing adoption and use of take-home naloxone (THN) as a primary response to DRD internationally the evidence base remains limited. METHODS: A systematic review and descriptive meta-analysis of the international THN literature was undertaken to determine an effect size for THN programmes. For each study, a proportion of use (PoU) was calculated using the number of 'peer administered uses' and the 'total number of participant/clients' trained and supplied with naloxone with a specific focus on people who use drugs (PWUD). This was constrained to a three month period as the lowest common denominator. As a percentage this gives the three month rate of use (per 100 participants). RESULTS: From twenty-five identified THN evaluations, nine studies allowed a PoU to be determined. Overall, the model shows a range of 5.2-13.1 (point estimate 9.2) naloxone uses every three months for every 100 PWUD trained. CONCLUSION: Our model estimates that around 9% of naloxone kits distributed are likely to be used for peer administration within the first three months of supply for every 100 PWUD trained. Future evaluations should directly compare different training structures to test relative effectiveness and use a series of fixed time periods (3, 6 and 12 months) to determine whether time since training affects rate of naloxone use.
Authors: Kristin E Schneider; Saba Rouhani; Noelle P Weicker; Miles Morris; Susan G Sherman Journal: Drug Alcohol Depend Date: 2022-02-17 Impact factor: 4.492
Authors: Alexandria Macmadu; Lisa Frueh; Alexandra B Collins; Roxxanne Newman; Nancy P Barnett; Josiah D Rich; Melissa A Clark; Brandon D L Marshall Journal: Int J Drug Policy Date: 2022-07-08
Authors: Jermaine D Jones; Aimee N Campbell; Laura Brandt; Verena E Metz; Suky Martinez; Melanie Wall; Thomas Corbeil; Howard Andrews; Felipe Castillo; Joanne Neale; John Strang; Stephen Ross; Sandra D Comer Journal: Drug Alcohol Depend Date: 2022-05-23 Impact factor: 4.852
Authors: Max Ferguson; Andrea Medley; Katherine Rittenbach; Thomas D Brothers; Carol Strike; Justin Ng; Pamela Leece; Tara Elton-Marshall; Farihah Ali; Diane L Lorenzetti; Jane A Buxton Journal: Harm Reduct J Date: 2022-07-02
Authors: Nicholas Baldwin; Roger Gray; Anirudh Goel; Evan Wood; Jane A Buxton; Launette Marie Rieb Journal: Drug Alcohol Depend Date: 2018-02-20 Impact factor: 4.492